GlaxoSmithKline reported 2.32B in Selling and Administration Expenses for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 2.84B 389M
Alcon AG ALC:SW 692M 37M
Amgen AMGN:US $ 1.25B 519M
AstraZeneca AZN:LN 2.5B 129M
Bayer BAYN:GR 3.52B 30M
Biogen BIIB:US $ 637.3M 42.3M
Bristol Myers Squibb BMY:US $ 1.67B 1.05B
Eli Lilly And LLY:US $ 1.58B 22.1M
Fresenius FRE:GR 1.27B 110M
Fresenius Medical Care FME:GR 712M 167.37M
Galapagos GLPG:NA 45M 6.62M
Genmab GEN:DC 201M 30M
Gilead Sciences GILD:US $ 1.06B 675M
GlaxoSmithKline GSK:LN 2.32B 609M
Glaxosmithkline GSK:US 2.32B 609M
GRIFOLS GRF:SM 257.14M 4.21M
H. Lundbeck A/S LUN:DC 1.5B 432M
Hikma Pharmaceutical HIK:LN 235M 6M
Merk MRK:US $ 2.41B 663M
Novartis NOVN:VX 3.52B 388M
Orion ORNBV:FH 60.1M 5.5M
Philips PHIA:NA 1.16B 283M
Recordati REC:IM 113.41M 1.9M
Regeneron Pharmaceuticals REGN:US $ 405.6M 102.1M